Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Abbv save search
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
Published: 2022-06-01 (Crawled : 15:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: 0.0%
rinvoq trials positive results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.98%
H: 0.0%
C: 0.0%
skyrizi disease lancet risankizumab results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.98%
H: 0.0%
C: 0.0%
rinvoq lancet results phase 3 ulcerative colitis
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
Published: 2022-05-23 (Crawled : 16:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
vraylar treatment positive phase 3 major depressive disorder
Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
rinvoq disease response one phase 3
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)
Published: 2022-04-05 (Crawled : 14:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.0%
H: 2.51%
C: 0.95%
topline positive results phase 3
AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
Published: 2022-03-10 (Crawled : 13:30) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
treatment pos migraine positive phase 3
Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
Published: 2022-02-24 (Crawled : 18:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -2.16%
H: 0.0%
C: 0.0%
rinvoq disease phase 3
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
disease phase 3
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021
Published: 2021-11-05 (Crawled : 16:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.28%
H: 0.51%
C: 0.39%
trials phase 3 risankizumab trial
AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Published: 2021-10-29 (Crawled : 12:15) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.31%
H: 0.0%
C: 0.0%
treatment phase 3 depression major depressive disorder
AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease
Published: 2021-10-28 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.01%
H: 1.39%
C: 1.18%
disease parkinson phase 3 trial levodopa
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
Published: 2021-10-07 (Crawled : 12:15) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.42%
H: 1.83%
C: 0.99%
phase 3
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
Published: 2021-10-07 (Crawled : 12:15) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.42%
H: 1.83%
C: 0.99%
phase 3
Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-17 (Crawled : 01:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-16 (Crawled : 23:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab
Published: 2021-09-15 (Crawled : 13:15) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.1%
H: 2.07%
C: 1.11%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: -2.29%
results phase 3
Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
Published: 2021-09-15 (Crawled : 13:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.1%
H: 2.07%
C: 1.11%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: -2.29%
results phase 3
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-08-19 (Crawled : 02:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.92%
H: 2.37%
C: 1.48%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.27%
H: 8.73%
C: 1.47%
treatment lung cancer positive therapy results cancer phase 3 trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.